Skip to content
Review Open access

Crosstalk between PI3K/AKT signaling and epigenetic regulation in hepatocellular carcinoma: molecular mechanisms and therapeutic opportunities

Oct 2026 · Frontiers in Cell and Developmental Biology · Vol 14 · 0 citations · 170 references
Medicine

Abstract

Hepatocellular carcinoma (HCC) is an aggressive malignancy, and most patients are diagnosed at intermediate or advanced stages. Targeted therapies, immunotherapies, and combination regimens have limited efficacy, creating a major clinical challenge. The phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway is frequently and persistently activated in HCC. Epigenetic modifications regulate gene expression without altering the DNA sequence and contribute to malignant progression. Aberrant epigenetic states sustain PI3K/AKT activation by silencing tumor-suppressor genes and activating oncogenic signaling. Conversely, activated PI3K/AKT signaling remodels the epigenome through several enzymes that mediate epigenetic modifications. This bidirectional interaction promotes HCC progression. This review examines how DNA methylation, non-coding RNAs, and histone modifications drive excessive PI3K/AKT pathway activation. It also assesses the more limited evidence that PI3K/AKT signaling regulates these enzymes and reviews recent progress in combining PI3K inhibitors with epigenetic-targeting agents. We then consider the main barriers to clinical translation, including biomarker selection, treatment scheduling, and nanocarrier-based co-delivery. Clarifying this reciprocal regulation may support more rational, individualized therapeutic strategies for HCC.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.